CDC's No. 2 official abruptly steps down

The agency cited "unforeseen family obligations" for the decision. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

February 23, 2026 Check out STAT+

Sponsored By

Melinda Deslatte/AP Ralph Abraham, No. 2 official at CDC, abruptly steps down The drama and chaos surrounding the leadership of the Centers for Disease Control and Prevention have taken another twist. By Helen Branswell STAT+ | FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications  "Plausible mechanism pathway" is to make it easier for individual gene-editing success stories like Baby KJ to be produced at a vastly wider scale. By Jason Mast and Lizzy Lawrence STAT+ | Pharma lobbyists focus on a surprising new target: the FDA FDA insists decisions are based on science, but lobbyists said they believe the odds of approval go up if a decision can be spun as a win for Trump. By Daniel Payne and Lizzy Lawrence SAUL LOEB / AFP via Getty Images STAT+ | Health care reform might be a focus in midterms. For Congress, pursuing it will be an uphill climb Passing legislation to lower costs would be politically popular, but Republicans would face a host of challenges in doing so. By John Wilkerson STAT+ | A provocative proposal asks the FDA to let some AI devices on the market without review A petition from Harrison.ai asks the FDA to exempt some new AI tools radiologists use to analyze medical images from routine premarket review. By Mario Aguilar and Katie Palmer STAT+ | Novo's next-gen obesity drug stumbles in Lilly comparison study Today's biotech news includes Novo's next-gen obesity drug, Gilead buying CAR-T therapy partner Arcellx, and more. By Meghana Keshavan Adobe Opinion: No one in health care should be called a 'provider' No one in health care should be called a 'provider.' It's a matter of ethics and professionalism. By Lois Snyder Sulmasy Women's heart attack risk rises even if arteries aren't as clogged as men's  Heart disease in women may trigger risk at lower plaque levels than in men, new study says, raising concerns coronary scans could understate the danger. By Elizabeth Cooney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser